We are live on
!
Find out more
SCM
Stonepine Capital Management Portfolio holdings
AUM
$177M
1-Year Est. Return
91.13%
This Fund
S&P 500
This Quarter
Est. Return
+16.86%
1 Year Est. Return
+91.13%
3 Year Est. Return
+230.7%
5 Year Est. Return
+260.67%
10 Year Est. Return
+2,169.5%
AUM
$177M
AUM Growth
-$72.5M
(-29%)
Cap. Flow
+$12.6M
Cap. Flow
% of AUM
7.11%
Top 10 Holdings %
Top 10 Hldgs %
44.39%
Holding
107
New
24
Increased
24
Reduced
27
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ELOX
Eloxx Pharmaceuticals
ELOX
|
+$5.07M |
| 2 |
Edesa Biotech
EDSA
|
+$3.85M |
| 3 |
Indivior Pharmaceuticals
INDV
|
+$3.63M |
| 4 |
Cabaletta Bio
CABA
|
+$2.85M |
| 5 |
MSLE
Satellos Bioscience
MSLE
|
+$2.69M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tenax Therapeutics
TENX
|
+$4.03M |
| 2 |
Zevra Therapeutics
ZVRA
|
+$2.46M |
| 3 |
XOMA
Xoma
XOMA
|
+$2.18M |
| 4 |
Abeona Therapeutics
ABEO
|
+$1.04M |
| 5 |
Inhibikase Therapeutics
IKT
|
+$1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 74.11% |
| 2 | Miscellaneous | 25.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Precision Optics
POCI
$48M
| $237K | 0.13% |
46,390
-53,610
| -54% | -$261K |
|
|
UPB
77
Upstream Bio Inc
UPB
$326M
| $231K | 0.13% |
33,432
-1,568
| -4% | -$13.1K |
|
|
RNTX
78
Rein Therapeutics
RNTX
$76.7M
| $227K | 0.13% |
+218,038
| New | +$264K |
|
79
Heron Therapeutics
HRTX
$65.4M
| $209K | 0.12% |
490,787
-911,404
| -65% | -$731K |
|
80
CNS Pharmaceuticals
CNSP
$8.37M
| $199K | 0.11% |
41,573
-19,427
| -32% | -$81.6K |
|
81
Humacyte
HUMA
$168M
| $181K | 0.1% |
+231,299
| New | +$214K |
|
|
KLRS
82
Kalaris Therapeutics
KLRS
$93.6M
| $123K | 0.07% |
30,122
+9,722
| +48% | +$50.5K |
|
83
Processa Pharmaceuticals
PCSA
$5.64M
| $106K | 0.06% |
55,000
| – | – |
|
|
BCAB
84
DELISTED
BIOATLA INC
BCAB
| $68K | 0.04% |
16,432
+15,124
| +1,156% | +$64.1K |
|
85
Compugen
CGEN
$245M
| $67.2K | 0.04% |
31,387
-72,913
| -70% | -$183K |
|
86
Ovid Therapeutics
OVID
$547M
| $57.3K | 0.03% |
21,300
-18,700
| -47% | -$48.3K |
|
|
EVAX
87
Evaxion A/S
EVAX
$26.1M
| $54.4K | 0.03% |
17,562
-2,151
| -11% | -$8.45K |
|
|
88
CALL
Abeona Therapeutics
ABEO
$343M
| – | – |
-100,000
| Closed | -$448K |
|
89
CALL
Acadia Pharmaceuticals
ACAD
$4.83B
| – | – |
-100,000
| Closed | -$2.23M |
|
90
CALL
Alexandria Real Estate Equities
ARE
$9.06B
| – | – |
-50,000
| Closed | -$2.32M |
|
91
Candel Therapeutics
CADL
$979M
| – | – |
-102,500
| Closed | -$502K |
|
92
CALL
CytomX Therapeutics
CTMX
$808M
| – | – |
-200,000
| Closed | -$940K |
|
93
Eledon Pharmaceuticals
ELDN
$245M
| – | – |
-35,000
| Closed | -$108K |
|
94
CALL
Establishment Labs
ESTA
$2.21B
| – | – |
-50,000
| Closed | -$2.84M |
|
|
95
Establishment Labs
ESTA
$2.21B
| – | – |
-6,000
| Closed | -$341K |
|
96
Janux Therapeutics
JANX
$1.24B
| – | – |
-20,000
| Closed | -$278K |
|
97
MannKind Corp
MNKD
$1.3B
| – | – |
-16,300
| Closed | -$52.9K |
|
98
Neumora Therapeutics
NMRA
$246M
| – | – |
-100,000
| Closed | -$190K |
|
99
OmniAb
OABI
$628M
| – | – |
-164,045
| Closed | -$258K |
|
100
SI-BONE Inc
SIBN
$830M
| – | – |
-14,964
| Closed | -$214K |
|
Similar funds
RP
MSA
HF
BFAG
CWP
MVM
CMP
JESC
Stonepine Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, Stonepine Capital Management held 107 positions worth $177M, down 29% from $250M the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Stonepine Capital Management deployed $12.6M of net new capital in Q2 2026, opening 24 new positions and adding to 24 existing holdings. Its largest new stake was Eloxx Pharmaceuticals: 397,160 shares worth $5.51M.
By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 46% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Tenax Therapeutics, an estimated $4.03M trimmed.
- Stonepine Capital Management's largest Q2 2026 buy was Eloxx Pharmaceuticals: 397,160 shares worth $5.51M.
- Stonepine Capital Management added most to Edesa Biotech in Q2 2026, an estimated $3.85M increase.
- Stonepine Capital Management's biggest Q2 2026 reduction was Tenax Therapeutics, cutting an estimated $4.03M.
- Stonepine Capital Management fully exited Xoma in Q2 2026, selling an estimated $2.18M.
- Stonepine Capital Management's ten largest holdings make up 44% of its $177M portfolio in Q2 2026.
- Stonepine Capital Management opened 24 new positions and closed 20 in Q2 2026.
- Stonepine Capital Management's portfolio value fell 29% quarter-over-quarter to $177M.
Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.